Drugs / OrienX010
OrienX010
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04197882 | May 2019 → May 2021 | melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 1 | NCT04206358 | May 2019 → Feb 2021 | melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 1 | NCT01935453 | May 2012 → May 2014 | liver cancer, lung cancer, malignant pancreatic neoplasm, melanoma | OrienGene Biotechnology Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04200040 | Aug 2017 → Dec 2022 | cutaneous melanoma | OrienGene Biotechnology Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OrienX010 | “The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.” NCT01935453 ↗ |
| Known as | ori | “This phase Ib trial study (Clinicaltrials.gov NCT04197882) assessed the efficacy and safety of the combination of neoadjuvant oncolytic virus orienX010 (ori) and anti-PD-1...” PMID 39572525 ↗ Nov 2024 |
| Known as | Recombinant Human GM-CSF Herpes Simplex Virus Injection | “The Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) in Combination with Recombinant Human Anti-PD1 Monoclonal Antibody Injection (JS001)” NCT04206358 ↗ |
| Route | Other | “intratumoral injection” NCT04206358 ↗ |